PHGEU Projected Dividend Yield

Unit 1 Com & 1 Wt Exp 10/16/2024/BiomX Inc ( AMEX : PHGEU )

BiomX is a clinical stage microbiome product discovery company developing products using both natural and engineered phage technologies designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in diseases, such as inflammatory bowel disease (IBD), liver disease and cancer. Co. is is developing BX001, its lead product candidate, to modify the appearance of skin in a range of skin types, including in oily and acne-prone skin. BX002 is Co.'s therapeutic phage product candidate designed to treat IBD. BX003 is Co.'s therapeutic phage product candidate targeting bacteria associated with primary sclerosing cholangitis, an inflammatory liver disease.

20 YEAR PERFORMANCE RESULTS